Article
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Blood - 22 Apr 2021
Falchi Lorenzo, Ma Helen, Klein Sandra, Lue Jennifer K, Montanari Francesca, Marchi Enrica, Deng Changchun, Kim Hye A, Rada Aishling, Jacob Alice T, Kinahan Cristina, Francescone Mark M, Soderquist Craig R, Park David C, Bhagat Govind, Nandakumar Renu, Menezes Daniel, Scotto Luigi, Sokol Lubomir, Shustov Andrei R, O'Connor Owen A
Abstract excerpt
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In a phase 1 trial, we found oral 5-azacytidine and romidepsin to be safe and effective, with lineage-selective activity among patients with relapsed/refractory (R/R) PTCL....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.